-
Cell Cycle (Georgetown, Tex.) May 2013
Topics: Animals; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Ubiquitin-Protein Ligases
PubMed: 23624838
DOI: 10.4161/cc.24748 -
JPMA. the Journal of the Pakistan... Dec 2021Myeloid Sarcomas are rare tumours of myeloid origin that may infiltrate multiple sites of the body. They may precede acute myeloid leukaemia or present without it. It...
Myeloid Sarcomas are rare tumours of myeloid origin that may infiltrate multiple sites of the body. They may precede acute myeloid leukaemia or present without it. It has non-specific manifestations and presents as a diagnostic and therapeutic challenge owing to the limited literature that reports consensus on diagnostic and treatment strategies. Immunohistochemistry is of significance in identifying the disease and acute myeloid leukaemia protocols of systemic therapy remain the mainstay of the treatment. Our report of an 11-year-old child with myeloid sarcoma aims to add to the limited existing literature and describe the varied presentation and sites of involvement.
Topics: Child; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Sarcoma, Myeloid
PubMed: 35150543
DOI: 10.47391/JPMA.460 -
Haematologica Jun 2010
Review
Topics: Animals; Humans; Leukemia, Myeloid, Acute; Stem Cell Transplantation; Transplantation, Homologous
PubMed: 20513804
DOI: 10.3324/haematol.2010.023184 -
Cytometry. Part B, Clinical Cytometry Sep 2012Flow Cytometry is the standard for the detection of glycosylphosphatidylinositol (GPI)-deficient clones in paroxysmal nocturnal hemoglobinuria (PNH) and related... (Comparative Study)
Comparative Study
BACKGROUND
Flow Cytometry is the standard for the detection of glycosylphosphatidylinositol (GPI)-deficient clones in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders. Although the International Clinical Cytometry Society (ICCS) and the International PNH Interest Group (IPIG) have published guidelines for PNH assays, data analysis has not been standardized. Current analyses use manual gating to enumerate PNH cells. We evaluate an automated approach to identify GPI-deficient leukocytes using a GemStone™ (Verity Software House) probability state model (PSM).
METHODS
Five hundred and thirty patient samples were assayed on BD Canto II flow cytometers using a stain-lyse-wash technique. Populations were defined using CD15, CD45, CD64 and side scatter. GPI-deficient myeloid cells were recognized as FLAER-, CD24-, and dim or absent CD16. GPI-deficient monocytic cells were identified as FLAER- and CD14-. The data were not censored in any way. A PSM was designed to enumerate monocytic and myeloid cells by adjusting the peaks and line spreads of the data, and recording the normal and GPI-deficient counts. No operator adjustments were made to the automated analysis.
RESULTS
By human analysis, 53 of 530 samples showed GPI-deficient clones. Automated analysis identified the same 53 clones; there were 0 false positives and 0 false negatives. Sensitivity was 100% and specificity 100%. Gating and automated results (percent GPI-deficient cells) were highly correlated: r² = 0.997 for monocytic cells, and r² = 0.999 for myeloids. Mean absolute differences were 0.94% for monocytes and 0.78% for myeloid cells.
CONCLUSIONS
Automated analysis of GPI-deficient leukocytes produces results that agree strongly with gate-based results. The probability-based approach provides higher speed, objectivity, and reproducibility.
Topics: Automation, Laboratory; Data Interpretation, Statistical; Flow Cytometry; Glycosylphosphatidylinositols; Hemoglobinuria, Paroxysmal; Humans; Leukocytes; Linear Models; Multivariate Analysis; Probability; Seizures; Software
PubMed: 22566361
DOI: 10.1002/cyto.b.21024 -
Haematologica Jan 2022
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute
PubMed: 34985228
DOI: 10.3324/haematol.2021.280161 -
Blood Jun 1983
Review
Topics: Antineoplastic Agents; Blood Platelets; Bone Marrow Examination; Cell Differentiation; Cell Division; Cells, Cultured; Clone Cells; Erythrocytes; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neutrophils; Preleukemia; Prognosis
PubMed: 6340754
DOI: No ID Found -
Blood Mar 2001
Topics: Humans; Leukemia, Myeloid, Acute; Radioactive Fallout; Translocation, Genetic
PubMed: 11263441
DOI: 10.1182/blood.v97.6.1897 -
Medicine May 2022Isolated myeloid sarcoma (MS) is characterized by the rapid proliferation of myeloblasts of acute myeloid leukemia (AML), without any blood or bone marrow involvement....
RATIONALE
Isolated myeloid sarcoma (MS) is characterized by the rapid proliferation of myeloblasts of acute myeloid leukemia (AML), without any blood or bone marrow involvement. This disease can manifest with extramedullary organ involvement, such as the skin, lymph nodes, bone, brain, breast cervix, and visceral organs, while the occurrence of myeloid sarcomas in the stomach is rare. Isolated MS has been associated with acute myeloid leukemia (AML), but the rapid progression of MS to acute myeloid leukemia with a complex karyotype and TLS-ERG fusion gene is even rarer.
PATIENT CONCERNS
A 33-year-old woman suffered from persistent epigastric pain accompanied by two months of anorexia and nausea, as well as 1-week of melena.
DIAGNOSIS
This patient was initially diagnosed with gastric MS that eventually transformed into AML with a complex karyotype and TLS-ERG fusion gene, 4 months later.
INTERVENTIONS
Only palliative care, including nutrition support, antacids, blood transfusion, anti-infection methods were used on this patient to determine the cachexia status and the family's requirement.
OUTCOMES
Routine follow-up results demonstrated this patient had died due to cerebral hemorrhage five months after the diagnosis of MS.
LESSONS
Comprehensive integration of patient history, imaging features, mass and bone marrow biopsy, and molecular cytogenetic may provide insights that could help us avoid the misdiagnosis of gastric MS. Isolated gastric MS can rapidly progress to AML with a poor prognosis if the patient does not receive appropriate treatment.
Topics: Adult; Female; Gene Fusion; Humans; Karyotype; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; RNA-Binding Protein FUS; Sarcoma, Myeloid; Soft Tissue Neoplasms; Stomach Neoplasms; Transcriptional Regulator ERG
PubMed: 35623083
DOI: 10.1097/MD.0000000000029475 -
Blood Advances Mar 2023
Oñate G, Bataller A, Garrido A, et al; CETLAM (Spanish Cooperative Group for the Diagnosis and Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes). Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882-890.
Topics: Humans; Prognosis; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Myelodysplastic Syndromes
PubMed: 36917130
DOI: 10.1182/bloodadvances.2022009604 -
Acta Dermato-venereologica May 2013We conducted a retrospective study of patients with cutaneous myeloid sarcoma, from 2 tertiary care institutions. Eighty-three patients presented, with a mean age of 52...
We conducted a retrospective study of patients with cutaneous myeloid sarcoma, from 2 tertiary care institutions. Eighty-three patients presented, with a mean age of 52 years. Diagnosis of myeloid sarcoma in the skin was difficult due to the low frequency of myeloperoxidase and/or CD34+ cases (56% and 19% of tested cases, respectively). Seventy-one of the 83 patients (86%) had ≥ 1 bone marrow biopsy. Twenty-eight (39%) had acute myeloid leukemia with monocytic differentiation. Twenty-three had other de novo acute myeloid leukemia subtypes. Thirteen patients had other myeloid neoplasms, of which 4 ultimately progressed to an acute myeloid leukemia. Seven had no bone marrow malignancy. Ninety-eight percent of the patients received chemotherapy, and approximately 89% died of causes related to their disease. Cutaneous myeloid sarcoma in most cases represents an aggressive manifestation of acute myeloid leukemia. Diagnosis can be challenging due to lack of myeloblast-associated antigen expression in many cases, and difficulty in distinguishing monocyte-lineage blasts from neoplastic and non-neoplastic mature monocytes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Biopsy; Bone Marrow Examination; Chi-Square Distribution; Child; Child, Preschool; Female; Flow Cytometry; Humans; Immunohistochemistry; Infant; Infant, Newborn; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Missouri; Predictive Value of Tests; Retrospective Studies; Sarcoma, Myeloid; Skin; Skin Neoplasms; Tertiary Care Centers; Time Factors; Treatment Outcome; Young Adult
PubMed: 23165700
DOI: 10.2340/00015555-1458